Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

被引：3
|
作者：
Spencer, Andrew [1 ]
Iversen, Katrine Fladeland [2 ]
Dhakal, Binod [3 ]
Creignou, Maria [4 ]
Chen, Jenny [5 ]
Hiemstra, Ida H. [6 ]
Bosgra, Sieto [6 ]
Badani, Avani [5 ]
Breij, Esther C. W. [6 ]
Brady, Lauren K. [5 ]
Sasser, A. Kate [5 ]
Malmberg, Anders [7 ]
Gregersen, Henrik [8 ]
Hansson, Markus [9 ]
Broijl, Annemiek [10 ]
Mateos, Maria-Victoria [11 ]
Plesner, Torben [2 ]
机构：
[1] Alfred Hosp, Melbourne, Vic, Australia
[2] Vejle Hosp, Vejle, Denmark
[3] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA
[4] Karolinska Univ Hosp, Dept Hematol, Huddinge, Sweden
[5] Genmab, Princeton, NJ USA
[6] Genmab, Utrecht, Netherlands
[7] Genmab, Copenhagen, Denmark
[8] Aalborg Univ Hosp, Dept Hematol, Aalborg, Denmark
[9] Aalborg Univ Hosp, Aalborg, Denmark
[10] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands
[11] USAL CSIC, Hosp Univ Salamanca, IBSAL, IBMCC, Salamanca, Spain
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-159116
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7320 / 7321
页数：2
相关论文
共 50 条
  • [41] Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.
    Rosenbaum, Cara Ann
    Stephens, Leonor Ano
    Kukreti, Vishal
    Zonder, Jeffrey A.
    Cole, Craig
    Zimmerman, Todd M.
    Reece, Donna Ellen
    Berdeja, Jesus G.
    Severson, Erica
    Revethis, Andrea
    Wolfe, Brittany
    McDonnell, Kathryn
    Nam, Jennifer
    Griffith, Kent A.
    Jakubowiak, Andrzej J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).
    Chari, Ajai
    Usmani, Saad Zafar
    Mateos, Maria-Victoria
    Van De Donk, Niels
    Kaufman, Jonathan L.
    Moreau, Philippe
    Rocafiguera, Albert Oriol
    Plesner, Torben
    Benboubker, Lotfi
    Liu, Kevin
    Hellemans, Peter
    Masterson, Tara J.
    Clemens, Pamela L.
    Farnsworth, Andrew
    Nahi, Hareth
    San-Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific 1-cell engager, in relapsed andfor refractory multiple myeloma (RRMM).
    Topp, Max S.
    Attal, Michel
    Langer, Christian
    Moreau, Philippe
    Facon, Thierry
    Dull, Johannes
    Hebraudt, Benjamin
    Gomez-Roca, Carlos
    Munzert, Gerd Michael
    Gracien, Edith
    Zugmaier, Gerhard
    Einsele, Hermann
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] A Phase 1 Dose-Escalation Study of Filanesib Plus Bortezomib and Dexamethasone in Patients With Recurrent/ Refractory Multiple Myeloma
    Chari, Ajai
    Htut, Myo
    Zonder, Jeffrey A.
    Fay, Joseph W.
    Jakubowiak, Andrzej J.
    Levy, Joan B.
    Lau, Kenneth
    Burt, Steven M.
    Tunquist, Brian J.
    Hilder, Brandi W.
    Rush, Selena A.
    Walker, Duncan H.
    Ptaszynski, Mieke
    Kaufman, Jonathan L.
    CANCER, 2016, 122 (21) : 3327 - 3335
  • [45] A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma
    Chakraborty, Rajshekhar
    Yan, Ying
    Royal, Mike
    BLOOD, 2021, 138
  • [46] A phase 1 dose-escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma
    Kumar, Anita
    Blum, Kristie A.
    Fung, Henry C.
    Smith, Mitchell R.
    Foster, Paul A.
    Younes, Anas
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (06) : 902 - 904
  • [47] A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results.
    Krishnan, Amrita Y.
    Patel, Krina K.
    Hari, Parameswaran
    Jagannath, Sundar
    Niesvizky, Ruben
    Silbermann, Rebecca Wang
    Berg, Deborah T.
    Li, Qing
    Allikmets, Kristina
    Stockerl-Goldstein, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).
    Berenson, James R.
    Cartmell, Alan
    Bessudo, Alberto
    Lyons, Roger M.
    Harb, Wael A.
    Tzachanis, Dimitrios
    Coleman, Morton
    Boccia, Ralph V.
    Rifkin, Robert M.
    Patel, Priti
    Dixon, Sandra
    Berdeja, Jesus G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1 b Study (NCT01999335)
    Shah, Jatin
    Niesvizky, Ruben
    Stadtmauer, Edward
    Rifkin, Robert M.
    Berenson, James
    Berdeja, Jesus G.
    Sharman, Jeff P.
    Lyons, Roger
    Klippel, Zandra
    Wong, Hansen
    Chang, Yu-Lin
    Usmani, Saad
    BLOOD, 2015, 126 (23)
  • [50] Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study (vol 150, pg 438, 2010)
    Richardson, P. G.
    Chanan-Khan, A. A.
    Alsina, M.
    Albitar, M.
    Berman, M.
    Messina, M.
    Mitsiades, C. S.
    Anderson, K. C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (06) : 731 - 731
12345